Your search history is turned on.
Date: April 25, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, North West Territories, Nunavut, Ontario, Price Edward Island, Saskatchewan, Yukon
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call TORONTO, April 25, 2024 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q1 fiscal 2024 financial results on Thursday, May 9, 2024. The Company will hold a conference call that same day at 8:30 a.m. ET ...
Date: April 12, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, North West Territories, Nunavut, Ontario, Price Edward Island, Saskatchewan, Yukon
Notice to Reader An Independent Auditors Report that inadvertently omitted the description Chartered Professional Accountants, Licensed Public Accountants within the signature of the auditor, was filed on March 13, 2024, with the Consolidated Financial Statements for the year ended December 31, 2023. We are therefore refiling the Consolidated Financ...
Date: April 9, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, North West Territories, Nunavut, Ontario, Price Edward Island, Saskatchewan, Yukon
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference TORONTO, April 9, 2024 /CNW/ - HLS Therapeutics Inc. (HLS or the Company) (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announc...
Date: April 8, 2024 Jurisdictions: All jurisdictions
April 08, 2024 100 University Avenue, 8th floor Toronto ON, M5J 2Y1 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: HLS THERAPEUTICS INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual Gener...
Date: April 8, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, North West Territories, Nunavut, Ontario, Price Edward Island, Saskatchewan, Yukon
New REDUCE-IT Analyses Show VASCEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups New REDUCE-IT Analyses Show VASCEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups Findings Presented on VASCEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels Lp(a) Results Published Simultaneously in the Journal ...
Date: March 14, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, HANNA, John, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable d...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
Date: March 14, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, New Brunswick, All Jurisdictions, Nova Scotia, North West Territories, Nunavut, Ontario, Price Edward Island, Saskatchewan, Yukon
1 Form 52-109F1 Certification of Annual Filings Full Certificate I, John Hanna, Chief Financial Officer of HLS Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated b...
1 Form 52-109F1 Certification of Annual Filings Full Certificate I, Craig Millian, Chief Executive Officer of HLS Therapeutics Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporate...
HLS THERAPEUTICS INC. ANNUAL INFORMATION FORM March 13, 2024 TABLE OF CONTENTS Page MEANING OF CERTAIN REFERENCES .................................................................................................................. 1 FORWARD-LOOKING STATEMENTS .....